PHARMACY MARKET

Twelve Consulting Group Announces Partnership with Celonis to Help Customers Identify and Eliminate Process Inefficiencies

Twelve Consulting Group, | February 11, 2022

Twelve Consulting Group, a consultancy firm specializingin designing and delivering cloud-based solutions, has formalized its partnership with Celonis, the global leader in execution management.

This partnership combines Twelve CG’s technology consulting expertise with Celonis’ market leading process mining and execution management capabilities, enabling customers to optimize their business operations, identify inefficiencies and unlock their full execution capacity.

The Celonis Execution Management System (EMS) provides companies with a modern way to understand and execute their business processes, eliminating billions of dollars in inefficiencies. The EMS powers all facets of business execution, including real-time data ingestion, process and task mining, planning and simulation, visualization and daily management, and targeted action flows to course correct in real-time.

By partnering with Celonis, we’ll be able to help our customers identify broken processes and execution gaps. And in addition, we can use the Celonis platform to fix those process issues and unlock efficiencies and value. This collaboration brings together the strengths of both organizations to deliver exceptional business outcomes and improve performance for our joint customers.”

Jon Howard, Director of Solution Innovation at Twelve CG

“Today’s businesses need to be able to see and understand processes before they can effectively act. Our Execution Management System helps customers identify and fix failing business processes, and addresses every facet of execution management from analytics, to strategy and planning, management, actions and automation,” said Nicole Gallant, VP Partner Management North America at Celonis. “Partnering with Twelve CG will help enterprises close the execution gaps that have been holding them back from achieving full execution capacity.”

About Twelve Consulting Group
Founded in 2013 by Jill King, Twelve Consulting Group leverages leading cloud-based technologies to help customers unlock potential with smarter data. Twelve CG works with 100+ customers across the CPG, Pharmaceutical and Technology industries to solve mission critical business challenges with speed, accuracy and agility. 

Spotlight

Innovative pharmaceutical companies engage in sophisticated strategies to moderate the loss of revenue they will face when generic competitors enter the market. Known in the industry as product lifecycle management, these strategies often rely on the development and launch of pharmaceutical line extensions. Line extensions are incremental innovations on the product facing generic competition, and usually enter the market with exclusivity periods that outlast those of the original product.


Other News
BUSINESS INSIGHTS

Vivera Enters $23 Billion Telehealth Industry with Patent Allowance for MDZone

Vivera Pharmaceuticals, Inc. | April 25, 2022

Vivera Pharmaceuticals, Inc. is pleased to announce that it has received a Notice of Allowance for U.S. Patent Application No. 17/066,985 entitled, "Self-Contained, Portable, Sanitization Device and Telemedicine Station," for the Company's MDZone platform from the United States Patent and Trademark Office. This Notice of Allowance indicates that the patent application has passed its examination for issuance. MDZone will be a HIPAA compliant, portable telemedicine station that will allow patients to access health care and connect with a medical provider remotely. Broadly patented for multiple points of utilization, MDZone will make health care more affordable and accessible than ever for communities across the country. Telehealth services and technology are often more convenient in terms of both scheduling and transportation than in-office visits and have been instrumental in improving access to medical care for many patients. Patients who can benefit from telehealth include those with mobility limitations or other challenges that can make it difficult to attend in-person doctor visits. Virtual care has also been considered a tool to increase accessibility to health care in rural communities where physician shortages are more prevalent. The COVID-19 pandemic accelerated the use of telehealth for various appointment types, including general wellness and preventative care, medication management, and pre-visit lab orders. Lockdowns, social distancing, hospitals at capacity, and delayed surgeries and routine preventative care visits have contributed to a current surge in serious illnesses and even an increased incidence of death from medical complications that could have been prevented. While telehealth won't completely replace in-office appointments, it is helping a health care system, stretched thin on everything from beds to staffing to heightened costs, with a more streamlined and effective touchpoint to provide patients with enhanced access to medical care. "The pandemic prompted a shift in the rapid adoption of telehealth services worldwide. A number of serious illnesses and even deaths could have been prevented if we had technology like MDZone available from the beginning of the pandemic to provide quality care to patients from the comfort of their homes, schools, or offices. Many people developed new medical conditions or experienced worsening of existing ones, and their suffering could have been prevented if we had the right systems in place." Paul Edalat, CEO of Vivera MDZone is designed to be a complete turn-key solution for health screenings. It can measure a patient's biometric data, including heart rate, blood pressure, and blood glucose, and allow the medical provider to provide interactive medical evaluation and feedback. If the measured values were outside of recommended ranges, the patient would be provided with a treatment plan, which could include dietary change suggestions, a prescription for medication, a lab order, or a recommendation for an in-person. "MDZone will give people access to health care as often as they need it without having to visit a doctor's office," said Vivera's Chief Medical Officer, Stephen J. McColgan, M.D., M.B.A. "In turn, they will be able to make real-time decisions about their treatment plan, translating to better patient outcomes." Even with patients returning to in-person doctor's office visits, the need for telehealth services is expected to continue increasing. In 2021, the U.S. telehealth market size was valued at $23.5 billion and is expected to expand at a compound annual growth rate (CAGR) of 44.4% from 2022 to 2028. In addition to making health care more accessible, MDZone will also make it more affordable. Vivera's technology can be life-changing for low-income communities and schools with limited resources. Many schools don't have a full-time on-site nurse. By utilizing the telemedicine station to conduct student health screenings, MDZone may eliminate the need to see a nurse in some instances while still providing quality care. Vivera maintains a solid intellectual property strategy with six patents granted and 26 patents pending. Receiving its patent for MDZone as a self-contained, portable telemedicine station will strengthen and expand the Company's patient-centric patent portfolio. About Vivera Pharmaceuticals Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT® sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH®, a smart dose-controlled medical device. It also has patents pending on its telemedicine station, MDZone. With multiple divisions, including its pharmaceutical, neurosciences, medical technology, biosciences, and advanced diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.

Read More

BUSINESS INSIGHTS

Integral Molecular and Optimeos Life Sciences Enter Partnership to Develop mRNA and DNA-Based Gene Therapies Using Molecular Targeting

Integral Molecular | June 09, 2022

Integral Molecular and Optimeos Life Sciences announce a partnership to develop next-generation mRNA and DNA therapeutics that will use antibody-based molecular targeting to direct vaccines and gene therapies to relevant tissues in a patient's body. This partnership combines Integral Molecular's experience in antibody discovery and mRNA immunization with Optimeos' technology for nanoparticle-based drug delivery systems. DNA and mRNA therapeutics harness a patient's own molecular machinery to encode proteins. Integral Molecular and Optimeos plan to encapsulate these therapeutic molecules within nanoparticle spheres that are decorated with antibodies on the outer surface. The antibodies can then target the particles to specific tissues. Currently, gene therapies and mRNA vaccines are delivered into the body via infusion or injection, but only a fraction of the molecules arrive at their intended site. The proposed molecular targeting strategy has the potential to transform the delivery of vaccines and therapeutics by dramatically reducing dosages, decreasing toxicity, and enabling scalable administration. Integral Molecular will apply its industry-leading antibody discovery expertise against complex cell-surface proteins to provide targeting moieties for the therapies. Its specialized MPS Antibody Discovery platform is tailored to work with challenging membrane protein targets and routinely uses mRNA-based immunization strategies. "Precision targeting of an isolated cell type with gene therapy holds great promise for genetic diseases and may provide brand-new directions in cancer immunotherapy including in vivo CAR-T cell therapeutics," said Joseph Rucker, Co-founder and VP of R&D at Integral Molecular. Optimeos' technology allows the robust and scalable incorporation of mRNA and DNA therapeutics and other biologics into customizable nanoparticles. "We are excited to work with Integral Molecular towards the next generation of gene-therapy that no longer relies on viral-based delivery systems," said Robert Prud'homme, Co-founder and Chief Technical Officer of Optimeos. Integral Molecular and Optimeos will be attending the BIO International Convention in San Diego later this month. About Integral Molecular Integral Molecular is the industry leader in developing and applying innovative technologies that advance the discovery of therapeutics against difficult protein targets. With 20 years of experience focused on membrane proteins and antibodies, Integral Molecular's technologies have been integrated into the drug discovery pipelines of over 400 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, autoimmune disorders, and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue viruses. About Optimeos Life Sciences Optimeos Life Sciences has developed a novel, highly differentiated, non-viral, nanoparticle technology, for delivery of new therapeutic drugs to address important unmet medical needs. The technology is a patented and scalable polymeric drug delivery system, which was developed and refined in Professor Prud'homme's lab at Princeton University over 20 years. Optimeos' technology enables encapsulation of mRNA, DNA, peptides, proteins or small molecules, as well as their targeted delivery to cells and tissues beyond the liver.

Read More

PHARMA TECH

IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology

IACTA Pharmaceuticals, Inc. | December 16, 2021

IACTA Pharmaceuticals, Inc. an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, announced that they are entering into a strategic collaboration and licensing agreement. The agreement grants IACTA the use of TALLC’s proprietary SmartCelle™ micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development. IACTA plans to utilize TALLC’s SmartCelle technology to deliver one or more of its novel ophthalmic therapeutics, as well as co-develop new ophthalmology therapeutic candidates that leverage IACTA’s formulation and clinical expertise with TALLC’s novel delivery technology. The collaboration also includes an option agreement, granting IACTA exclusive rights to negotiate a separate license agreement for the right to co-develop TALLC’s lead product candidate TA-A001, a novel anti-inflammatory anti-angiogenic molecule with analgesic properties in various disease state models. “I am thrilled to be able to partner with TALLC, a company with a shared vision focused on addressing the growing and significantly underserved ocular pain market. IACTA was formed with the mission of developing and commercializing innovative ocular therapies through novel compounds and utilizing leading drug delivery technologies, and we view this collaboration as the perfect synergy to realize the full potential of our ophthalmology pipeline. We are excited to explore how best to deploy the SmartCelle technology within our current pipeline, as well as the future co-development opportunities this partnership provides.” Damon Burrows, Chief Executive Officer of IACTA Pharmaceuticals TALLC’s proprietary SmartCelle pan-ocular drug delivery technology employs 30nm micelles that enable delivery of difficult to formulate drugs into corneal and retinal tissues after topical delivery. The company’s pipeline is led by SmartCelle TA-A001, a novel CB2 receptor activator, delivered topically to treat the effects of dry eye syndrome and age-related macular degeneration. “We are delighted to partner with the IACTA team for this important program. IACTA, with its in depth scientific and commercial understanding of the ophthalmic space is an ideal partner for TALLC as we drive towards further commercialization of the SmartCelle platform and TA-A001,” said Damon Smith, Ph.D., Chief Executive Officer of TALLC. “We look forward to working closely with the IACTA team and to co-developing SmartCelle versions of the IACTA pipeline.” About TALLC, Inc. TALLC is a Montreal-based developer of ophthalmic medicines actively engaged in the commercialization of SmartCelle TA-A001, and its pipeline of SmartCelle-delivered drug candidates, as treatments for acute and chronic inflammation. Focused initially on unmet needs in inflammatory front of eye indications, TALLC plans also to develop SmartCelle TA-A002 and TA-A003 in other chronic conditions including macular degeneration and glaucoma. SmartCelle enables pan ocular delivery of drug candidates by topical application directly to the ocular surface, by injection or by insufflation. About IACTA Pharmaceuticals, Inc. IACTA is an innovation leader in ophthalmic therapeutics, led by former top executives from one of the leading eye care companies in the world. The company currently has four products in development for major market opportunities. IC 800 is a novel, non-opioid, dual enkephalinase inhibitor, being studied for the treatment of acute ocular pain. In addition, IACTA’s IC 265, is a SYK kinase inhibitor being developed as a potential novel treatment for dry eye disease.

Read More

BUSINESS INSIGHTS

MedX Health Announces Addition of Two New Screening Services Locations in Ottawa

MedX Health Corp | January 28, 2022

Teledermatology company MedX Health Corp. is pleased to announce the launch of MedX Screening Services to be offered at two locations in Ottawa, Canada – ProMed Pharmacy, an independent, pharmacist owned pharmacy enterprise, and Dura Wellness Clinic a retail, clinical focused esthetic services group. Both locations will now offer MedX scanning services and accept walk-in patients. "This represents the next step in our business plan for North America. ProMed Pharmacy, under the Leadership of Lubna Fawaz, is a perfect model of modern health care delivery as it integrates many services and, most importantly, telehealth services on demand for their patients. Patients can now enter the pharmacy and have a telemedicine consult with a General Practitioner and receive an immediate referral to the Dermsecure Screening Service on site. Incorporating a telemedicine consult with a General Practitioner is a vital step to make DermSecure screening services easily accessible to the public by facilitating both the referral and the screening at the same location." MedX VP of North American Sales, Paul Ziemer The addition of ProMed Pharmacy to MedX's Pharmacy network will allow for the "Walk-in-Patient" to get service for their Dermatology concerns if they do not have a Family Doctor or do not have time to get a direct referral. "MedX remains focused on expanding its footprint into existing and new target markets, and our team is continuing to establish and accelerate many new commercial relationships and partnerships," stated Mike Druhan, MedX President, Dermatology Services. "I remain confident in our team’s ability to expand MedX's teledermatology platform to new markets and greatly improve outcomes for those dermatology patients seeking high-quality, virtual services." Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. MedX is a global leader in teledermatology through its high-definition image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX's SIAscopy® is the only technology globally that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images 2mm below the skin's surface. This technology provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within 72 hours. About MedX Health Corp MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey.

Read More

Spotlight

Innovative pharmaceutical companies engage in sophisticated strategies to moderate the loss of revenue they will face when generic competitors enter the market. Known in the industry as product lifecycle management, these strategies often rely on the development and launch of pharmaceutical line extensions. Line extensions are incremental innovations on the product facing generic competition, and usually enter the market with exclusivity periods that outlast those of the original product.

Resources